

( (S (PP Regarding
	 (NP (NP your Oct. 4 page-one article)
	     ``
	     (NP-TTL Bad Blood)
	     ''
	     (PP on
		 (NP the generic-drug battle))))
     :
     (NP-SBJ The Epilepsy Institute)
     (VP is not
	 (NP-PRD just a patient-advocacy organization))
     .))
( (S (NP-SBJ It)
     (VP is
         (ADVP primarily)
         (NP-PRD (NP a certified outpatient treatment facility)
		 (VP providing
		     (NP comprehensive services)
		     (PP-DTV to
			     (NP (NP (NP people)
				     (PP with
					 (NP epilepsy)))
				 and
				 (NP their families))))))
     .))
( (S (NP-SBJ-1 (NP The institute 's)
               advocacy efforts)
     (VP are
         (VP based
             (NP *-1)
             (PP-CLR on
		     (NP (NP the needs)
			 (PP of
			     (NP (NP the population)
				 (SBAR (WHNP-2 0)
				       (S (NP-SBJ it)
					  (VP serves
					      and
					      represents
					      (NP *T*-2))))))))))
     .))
( (S (PP-TMP In
	     (NP 1985))
     ,
     (NP-SBJ the Medical Tribune)
     (VP reported
         (SBAR that
               (S (NP-SBJ (NP a growing number)
                          (PP of
                              (NP critics)))
                  (VP are
                      (VP challenging
                          (NP the FDA bioequivalence-therapeutic-equivalence equation))))))
     .))
( (S ``
     (S-TPC-4 (NP-SBJ They)
	      (VP contend
		  (SBAR 0
			(S (NP-SBJ-1 it)
			   (VP is
			       (VP based
				   (NP *-1)
				   (PP-CLR on
					   (NP (NP an assumption)
					       (SBAR (WHNP-3 that)
						     (S (NP-SBJ-2 *T*-3)
							(VP has not
							    (ADVP yet)
							    (VP been
								(VP proven
								    (NP *-2)
								    (PP-LOC in
									    (NP valid tests)))))))))))))))
     ,
     ''
     (NP-SBJ the Tribune)
     (VP said
	 (S *T*-4))
     .))
( (S (PP-TMP In
	     (NP 1986))
     ,
     (NP-SBJ some institute patients)
     (VP were
         (VP reporting
             (NP breakthrough seizures)
             (SBAR-TMP (WHADVP-2 when)
		       (S (NP-SBJ-1 they)
			  (VP were
			      (VP (VP switched
				      (NP *-1)
				      (PP-CLR-3 from
						(NP a specific brand-name medication))
				      (PP-CLR-4 to
						(NP a generic one)))
				  or
				  (VP (PP-CLR=3 from
						(NP (NP one generic manufacturer)
						    (PP of
							(NP a specific product))))
				      (PP-CLR=4 to
						(NP another)))
				  (ADVP-TMP *T*-2)))))))
     .))
( (S (PP In
         (NP addition))
     ,
     (NP-SBJ-1 neurologists)
     (VP were
         (VP beginning
             (S (NP-SBJ *-1)
                (VP to
                    (VP report
                        (NP these observations)
			(ADVP as
			      well))))))
     .))
( (S (NP-SBJ *)
     (VP Call
         (S (NP-SBJ it)
	    (ADJP-PRD anecdotal))
         (SBAR-ADV if
		   (S (NP-SBJ you)
		      (VP will
			  (VP *?*)))))
     .))
( (S But
     (NP-SBJ-2 no ethical physician)
     (VP would
         (VP switch
             (NP (NP patients)
                 (SBAR (WHNP-1 who)
                       (S (NP-SBJ *T*-1)
                          (VP were
                              (VP doing
                                  (ADVP-MNR well)
                                  (PP on
                                      (NP (NP a specific medication)
                                          (PP from
                                              (NP a specific manufacturer)))))))))
	     (S-PRP (NP-SBJ *-2)
		    (VP to
			(VP prove
			    (NP a point))))))
     .))
( (S (NP-SBJ We)
     (VP do not
         (VP depend
             (PP-CLR on
		     (NP pharmaceutical companies))
             (PP for
                 (NP our support))))
     .))
( (S (NP-SBJ The institute)
     (VP (VP has
             (NP (NP governmental service contracts)
                 (PP for
                     (NP (NP the provision)
                         (PP of
                             (NP direct patient services))))))
         ;
         (VP collects
             (NP patient fees))
         ;
         (VP receives
             (NP money)
             (PP-MNR through
		     (NP (NP contributions)
			 (PP from
			     (NP individuals
				 ,
				 foundations
				 and
				 bequests))))))
     .))
( (S (S (NP-SBJ-1 (NP The funds)
		  (VP received
		      (NP *)
		      (PP-CLR from
			      (NP pharmaceutical firms))))
        (VP are
            (VP used
		(NP *-1)
                (S-CLR (NP-SBJ *)
		       (VP to
			   (VP offset
			       (NP physician symposiums)))))))
     , and
     (S (NP-SBJ these symposiums)
        (VP do not
            (VP stress
                (NP any particular medication or manufacturer))))
     .))
( (S (NP-SBJ (NP (NP The Epilepsy Institute 's)
		 reporting)
             (PP of
                 (NP breakthrough seizures)))
     (VP stemmed
         (PP-CLR from
		 (NP (NP concerns)
		     (PP about
			 (NP (NP the people)
			     (SBAR (WHNP-1 0)
				   (S (NP-SBJ we)
				      (VP (VP treat
					      (NP *T*-1))
					  and
					  (VP care
					      (PP-CLR about
						      (NP *T*-1)))
					  (ADVP-TMP daily)))))))))
     .))
( (S (NP-SBJ-1 This)
     (ADVP perhaps)
     (VP was
         (VP perceived
             (NP *-1)
             (PP-CLR as
		     (UCP (NP a `` bold '' stance)
			  , and thus
			  (ADJP suspicious)))))
     .))
( (S But
     (NP-SBJ *)
     (VP let
         (S (NP-SBJ us)
	    not
	    (VP confuse
		(NP (NP profits)
		    (PP of
			(NP big business))
		    (VP masquerading
			(PP-CLR as
				(NP (NP concerns)
				    (PP (PP for
					    (NP (NP people 's)
						health care))
					or
					(PP for
					    (NP the cost))))))))))
     .))
( (SBARQ (WHPP-1 For
		 (WHNP whom))
	 (SQ is
	     (NP-SBJ the saving)
	     (PP-PRD *T*-1))
         ?))
( (FRAG (ADVP Surely)
	not
	(PP to
	    (NP (NP people)
		(PP with
		    (NP epilepsy))
		(SBAR (WHNP-1 who)
		      (S (NP-SBJ-2 *T*-1)
			 (VP depend
			     (PP-CLR on
				     (NP (NP the same levels)
					 (PP of
					     (NP medication))
					 (PP-LOC in
						 (NP their bloodstream))))
			     (ADVP-TMP daily)
			     (S-PRP (NP-SBJ *-2)
				    (VP to
					(VP maintain
					    (NP seizure control)))))))))
	.))
( (NP Reina Berner))
( (NP Executive Director))
( (NP Arnold M. Katz)) 
